Abstract
In July 2022, the ongoing monkeypox (MPX) outbreak was declared a public health emergency of international concern by the World Health Organization. Modified vaccinia virus Ankara (MVA-BN, also known as Imvamune, Jynneos, or Imvanex) is a 3rd generation smallpox vaccine that was generated by serial passaging of the more pathogenic parental vaccinia virus (VACV), and is authorized as a vaccine against MPX in humans in a two-shot regimen. Up to now, there is a lack of data that demonstrate MPX virus (MPXV)-neutralizing antibodies in vaccinated individuals and vaccine efficacy data against MPXV infection. Here, we measure MVA-, VACV-, and MPXV-reactive binding and neutralizing antibodies with validated in-house assays in cohorts of historically smallpox-vaccinated, MPXV PCR-positive, and recently MVA-BN-vaccinated individuals. We show that MPXV neutralizing antibodies were detected across all cohorts in individuals with MPXV exposure as well as those who received historic (VACV) vaccination. However, a primary MVA-BN immunization series in non-primed individuals yields relatively low levels of MPXV neutralizing antibodies. As the role of MPXV neutralizing antibodies for protection against disease and transmissibility is currently unclear and no correlate of protection against MPXV infection has been identified yet, this raises the question how well vaccinated individuals are protected. Dose-sparing leads to lower antibody levels, whereas a third MVA vaccination further boosts the antibody response. Cohort studies following vaccinated individuals are necessary to further assess vaccine efficacy in risk populations and determine correlates of protection for this emerging pathogen.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
https://trialsearch.who.int/Trial2.aspx?TrialID=NTR3401
Funding Statement
This work was partially funded from European Unions Horizon 2020 Grant ECRAID (grant no 965313), in preparation for possible clinical studies and trials following the decision to activate ECRAID to outbreak mode 2. Sequencing work was supported by European Unions Horizon 2020 Grant VEO (Grant No. 874735).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We have used 4 different serum panels in this manuscript. The first two serum panels consisted of an anonymized age-panel cohort to validate the assays, the second panel consisted of anynomized sera tested in standard diagnostics. The Erasmus MC Medical Ethics Committee waived ethical approval for use of these anonymized samples. The The 3rd panel consisted of sera obtained from Imvanex-vaccinated healthcare workers. These HCW were vaccinated as employees of a BSL3-laboratory for safety reasons, and samples were collected on a biobanking study protocol. The Erasmus MC Medical Ethics Committee gave ethical approval for this work performed in the COVA study (ethical permit MEC-2014-398). Finally, the 4th serum panel consisted of sera obtained in a phase I clinical trial with MVA-H5. The Erasmus MC Medical Ethics Committee gave ethical approval for this work performed in the FluVec-H5 study (ethical permit METC NL37002.000.12, clinical trial registry https://trialsearch.who.int/Trial2.aspx?TrialID=NTR3401).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
